Introduction

In a groundbreaking development, Dr. Laura Bukavina, MD, MPH, has unveiled details about the ongoing RAD-SG trial (NCT05833867) aimed at evaluating the safety and tolerability of combining adaptive radiation therapy with the investigational drug sacituzumab govitecan for patients battling muscle-invasive bladder cancer (MIBC). This innovative trial was presented at the prestigious 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium held in San Francisco, California.

Significance of the Trial

Why is this trial so significant? For many patients with MIBC who cannot undergo the conventional tri-modal therapy—which typically includes transurethral resection of bladder tumor (TURBT), radiation, and cisplatin-based chemotherapy—this combination offers a potentially life-saving bladder-preserving alternative.

Trial Details

The RAD-SG trial aims to recruit 20 participants who will receive 8 mg/kg of intravenous sacituzumab govitecan on days 1 and 8 of a 21-day treatment cycle, alongside adaptive radiation therapy. The intensity of this dual approach may not only increase the likelihood of successful outcomes but could also redefine treatment protocols in the cancer community.

Research Focus

The primary focus of this research will be to determine the rate of acute dose-limiting toxicities that patients might experience. Additionally, secondary outcomes include assessing bladder intact event-free survival, as well as evaluating potential biomarkers of response. Investigators will closely monitor the correlation between pre-treatment imaging and treatment responses, alongside changes in imaging throughout the trial.

Looking Ahead

With the primary completion of the study slated for December 2025, researchers and patients alike are eagerly anticipating the results of this innovative approach. As this trial unfolds, it holds the promise of a new horizon for those affected by this challenging disease, possibly leading to more effective and personalized cancer treatments in the near future.

Conclusion

Stay tuned for more updates on this pivotal research that could change the landscape of bladder cancer treatment!